Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Current Deferred Revenue (2017 - 2025)

ProQR Therapeutics' Current Deferred Revenue history spans 6 years, with the latest figure at $20.4 million for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 12.86% to $20.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.4 million, a 12.86% decrease, with the full-year FY2025 number at $20.4 million, down 12.86% from a year prior.
  • Current Deferred Revenue hit $20.4 million in Q4 2025 for ProQR Therapeutics, down from $23.4 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for PRQR hit a ceiling of $23.4 million in Q4 2024 and a floor of $5.8 million in Q4 2022.
  • Historically, Current Deferred Revenue has averaged $15.5 million across 5 years, with a median of $20.4 million in 2025.
  • Biggest five-year swings in Current Deferred Revenue: soared 601.1% in 2021 and later dropped 12.86% in 2025.
  • Tracing PRQR's Current Deferred Revenue over 5 years: stood at $5.9 million in 2021, then fell by 1.64% to $5.8 million in 2022, then soared by 284.54% to $22.1 million in 2023, then rose by 5.95% to $23.4 million in 2024, then dropped by 12.86% to $20.4 million in 2025.
  • Business Quant data shows Current Deferred Revenue for PRQR at $20.4 million in Q4 2025, $23.4 million in Q4 2024, and $22.1 million in Q4 2023.